ArticleFrontiers in bioengineering and biotechnology2026
Bioprinted skin: from lab bench to clinic, what matters now and what's next.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioprinted skin has emerged as a disruptive technology at the intersection of tissue engineering and plastic surgery. Through controlled deposition of bioinks containing living cells and biomaterials, it is now possible to create human skin constructs with unprecedented physiological fidelity. These constructs are already transforming the evaluation of drugs and cosmetics by providing reproducible, human-relevant alternatives to animal testing. In reconstructive and aesthetic surgery, bioprinted skin holds the promise of patient-specific grafts that integrate seamlessly, accelerate healing, and minimize scarring and pigmentation mismatch. This article explores the clinical, technical, and translational dimensions of bioprinted skin, with particular emphasis on fabrication strategies, bioink design, and current limitations. It further highlights the role of imaging, artificial intelligence, and advanced biomaterials in accelerating clinical translation while critically discussing the challenges that still prevent widespread implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.